Medical College of Wisconsin — Biomedical Watch V2

Traitements11programmes

Essais4liés

Publications5liées

SourceDBlocale

Traitements

11

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
1 X 10^6 cells/kgThis is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.	SEP	Phase 1	Immunomodulation	United States	À vérifier
2.5 X 10^6 cells/kgThis is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.	SEP	Phase 1	Immunomodulation	United States	À vérifier
Dose expansion: The maximum tolerated dose of CAR-T cellsThis is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.	SEP	Phase 1	Thérapie cellulaire + Immunomodulation	United States	À vérifier
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialThe purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical activity.	Cancer	Non applicable	Traitement symptomatique	United States	À vérifier
Repeat Dose TheophyllineAcute kidney injury is a significant complication for infants who experience hypoxic ischemic encephalopathy, being associated with increased rates of death and prolonged hospitalization. This pilot study of theophylline administration soon after birth for the prevention of kidney injury will lay the foundation for the conduct of a larger clinical trial that seeks to identify a theophylline as a novel therapy to prevent kidney injury in thousands of at-risk infants.	SEP	Phase 1/2	À vérifier	United States	À vérifier
Single Dose TheophyllineAcute kidney injury is a significant complication for infants who experience hypoxic ischemic encephalopathy, being associated with increased rates of death and prolonged hospitalization. This pilot study of theophylline administration soon after birth for the prevention of kidney injury will lay the foundation for the conduct of a larger clinical trial that seeks to identify a theophylline as a novel therapy to prevent kidney injury in thousands of at-risk infants.	SEP	Phase 1/2	À vérifier	United States	À vérifier
SPIO® Core-MAX® Expedition thoracolumbosacral orthosisThe purpose of this study is to determine the impact of the SPIO® Core-MAX® Expedition orthosis on an infant's head, trunk and upper limb function.	Myopathies	À vérifier	À vérifier	United States	À vérifier
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialThe purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical activity.	Cancer	Non applicable	Traitement symptomatique	United States	À vérifier
SPIO® Core-MAX® Expedition thoracolumbosacral orthosisThe purpose of this study is to determine the impact of the SPIO® Core-MAX® Expedition orthosis on an infant's head, trunk and upper limb function.	Myopathies	À vérifier	À vérifier	United States	À vérifier
Single Dose TheophyllineAcute kidney injury is a significant complication for infants who experience hypoxic ischemic encephalopathy, being associated with increased rates of death and prolonged hospitalization. This pilot study of theophylline administration soon after birth for the prevention of kidney injury will lay the foundation for the conduct of a larger clinical trial that seeks to identify a theophylline as a novel therapy to prevent kidney injury in thousands of at-risk infants.	SEP	Phase 1/2	À vérifier	United States	À vérifier
1 X 10^6 cells/kgThis is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.	SEP	Phase 1	Immunomodulation	United States	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
1 X 10^6 cells/kg	SEP	Phase 1	NCT07335328	Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies	NOT_YET_RECRUITING
Single Dose Theophylline	SEP	Phase 1/2	NCT05853601	TheoPHyLNNe — Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage	ACTIVE_NOT_RECRUITING
SPIO® Core-MAX® Expedition thoracolumbosacral orthosis	Myopathies	À vérifier	NCT06027580	Orthosis to Improve Trunk Control in Infants Age 6-18 Months	COMPLETED
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial	Cancer	Non applicable	NCT07227077	Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial	RECRUITING

Publications

5

Molécule	Indication / population	Titre	Journal	Date
Dose expansion: The maximum tolerated dose of CAR-T cells		Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.	Blood
Dose expansion: The maximum tolerated dose of CAR-T cells		Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial.	European journal of cancer (Oxford, England : 1990)
Single Dose Theophylline		Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.	Clinical pharmacology and therapeutics
Single Dose Theophylline		In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.	Clinical pharmacokinetics
Single Dose Theophylline		The neurophysiological effects of single-dose theophylline in patients with chronic stroke: A double-blind, placebo-controlled, randomized cross-over study.	Restorative neurology and neuroscience